Palatin Technologies with ticker code (PTN) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 3 and 1.5 calculating the mean target price we have 2.17. Now with the previous closing price of 0.53 this would imply there is a potential upside of 309.4%. The 50 day moving average now sits at 0.55 while the 200 day moving average is 0.55. The market cap for the company is $114m. Find out more information at: http://www.palatin.com
Palatin Technologies, a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor agonist, which has completed Phase III trial for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor 1 (MCr) agonist peptide that has completed Phase I clinical trial for inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease. Further, it is involved in developing MC4r agonist peptide and small molecule for the treatment of rare genetic metabolic and obesity disorders. Additionally, the company engages in the development of PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. Palatin Technologies was founded in 1986 and is based in Cranbury, New Jersey.